Methylphenidate Hydrochloride Laboratorios Rubio Sa (Methylphenidate Hydrochloride)

The medication blocks the reuptake of dopamine and norepinephrine by inhibiting their transporters (DAT and NET). This increases the concentration of these neurotransmitters in the synaptic cleft, enhancing signaling in brain regions that regulate attention, impulse control, and arousal.

The appropriate dose is individualized by the prescribing clinician based on factors such as the patient’s age, weight, severity of symptoms, response to therapy, and any co‑existing medical conditions. No fixed regimen is provided here; the prescriber sets the dosage.

Safety data for use in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both classes increase dopamine and norepinephrine activity, but methylphenidate primarily blocks reuptake transporters, whereas amphetamines also promote release of these neurotransmitters. Clinical response, side‑effect profiles, and individual tolerability can differ, so selection is based on patient‑specific factors.

Store the oral formulation at ambient temperature below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Methylphenidate Hydrochloride is taken orally, usually in tablet or capsule form, as directed by a healthcare professional. It should be swallowed whole with water and taken at the prescribed times, typically in the morning to avoid interference with sleep.

Serious adverse events include cardiovascular complications such as hypertension, chest pain, or arrhythmias, as well as psychiatric effects like psychosis or severe mood changes. Any sudden chest discomfort, severe anxiety, or hallucinations should prompt immediate medical evaluation.

Individuals with known hypersensitivity to methylphenidate, those taking monoamine oxidase inhibitors (MAOIs) within the past 14 days, patients with severe anxiety, uncontrolled hypertension, or certain cardiac conditions should avoid this medication unless specifically advised by a physician.